Position of the Transparency Council – Glypvilo (vildagliptin)
At its meeting on 20 February 2023, the Transparency Council adopted Position No. 19/2023 on the evaluation of the medicine Glypvilo (vildagliptin) for the indication: treatment of type 2 diabetes mellitus.